We came across a bullish thesis on United Therapeutics Corporation on BioEquity Watch’s Substack. In this article, we will summarize the bulls’ thesis on UTHR. United Therapeutics Corporation's share was trading at $471.99 as of January 15th. UTHR’s trailing and forward P/E were 17.89 and 15.15 respectively according to Yahoo Finance.
[caption id="attachment_571480" align="aligncenter" width="750"]United Therapeutics Corporation is a commercial-stage biotechnology company built around treprostinil, a prostacyclin analogue that drives...
Create a free account, or log in to read the full article
No credit card required.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.